Ashvattha Therapeutics, Inc.
5 clinical trials · Sponsor
◉ Watch Ashvattha Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| Study Evaluating Safety & Tolerability of Migaldendranib in Healthy Volunteers (NCT07370155) | Ashvattha Therapeutics, Inc. | 2026-01-29 |
| Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers (NCT05395624) | Ashvattha Therapeutics, Inc. | 2023-02-02 |
| Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME (NCT05387837) | Ashvattha Therapeutics, Inc. | 2022-08-31 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants (NCT05105607) | Ashvattha Therapeutics, Inc. | 2022-01-11 |
| A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients (NCT04458298) | Ashvattha Therapeutics, Inc. | 2020-08-11 |
Track Ashvattha Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.